European Commission logo
English English
CORDIS - EU research results

EDV2209 – a Paradigm shift in the treatment of stroke.

Project description

A new treatment for stroke

A stroke is caused when the blood supply to part of the brain is interrupted, leading to tissue damage. Currently, there are no effective treatments for stroke; only rehabilitation approaches to treat resulting neurological impairment. Funded by the European Innovation Council, the EDVance project will undertake a clinical trial on the disruptive new drug EDV2209. This drug is a result of years of research on cerebral blood circulation and stroke and functions by maintaining the blood vessels in the brain open to oxygen and nutrients. Preventing brain tissue damage after stroke is paramount for minimising its devastating consequences.


Despite tremendous research efforts and a large number of clinical trials focused on developing treatments for stroke, the field's current state remains dismal. There are, at present, no efficient treatments nor promising drug candidates for this lethal and disabling condition. A different perspective with a new approach is therefore desperately needed. Edvince's drug discovery and development is born out of founder and Professor Lars Edvinsson's extensive, fundamental and pioneering research of cerebral circulation, receptor regulation, stroke and migraines. Edvince is now ready to conduct the first clinical trial in 2022 with its innovative and disruptive lead drug EDV2209, an orphan drug for the treatment of brain ischemia associated with severe subarachnoid hemorrhage (SAH). The drug helps to keep the blood vessels in the brain open, allowing brain cells to receive oxygen and nutrients to prevent brain damage.


Net EU contribution
€ 2 500 000,00
223 81 Lund

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 4 422 831,25